THOMAS JEFFERSON UNIVERSITY

Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial.

Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care.

The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.

Researchers at Sidney Kimmel Cancer Center are developing an innovative anti-MDM2 PROTAC therapy that targets p73 activation to induce cancer cell death in p53-mutated tumors.

• Xaluritamig, a STEAP1-targeted T-cell engager, demonstrates significant clinical activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. • The optimized dosing schedule of Xaluritamig, involving step dosing to 1.5 mg every other week, improves tolerability and reduces musculoskeletal-related adverse events. • Clinical trials show impressive response rates, including in patients with liver metastases, with durable outcomes comparable to existing treatments like the VISION trial. • A phase 3 trial is planned to compare Xaluritamig to standard therapies, with potential to change clinical practice in late-stage prostate cancer management.